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ABSTRACT 
Thls study was an open-label, uncontrolled, dose-escalation trial of 
beta-blockers ln patients with a history of syncope without warning 
or syncope resulting in trauma (malignant vasovagal syncope) who 
had positive head-up tilt test (HUT) responses, with or without iso- 
proterenol infusion. Thirty patients (mean age, 37 * 21 years) with 
recurrent syncopal and near-syncopsl episodes of unexplained ori- 
gin in the previous year (6 * 14 syncopal episodes and 17 * 3 near- 
syncopes) underwent HUT for diagnostic purposes and for guiding 
prophylactic treatment. After patients were given a lo-minute rest 
in a recumbent position, we performed an HUT at 70” for 25 minutes; 
lf indicated, isoproterenol testing was performed at incremental 
dosages (five steps at lo-minute intervals at SO’). All patients ex- 
perienced syncope during HUT., 15 (50%) at baseline HUT and 15 
(50%) during isoproterenol infusion (1 to 3 pg/mim mean, 1.6 ug/ 
min). Sixteen syncopes were of vasodepressor type, 10 were mixed, 
and 4 were of cardioinhibitory type. After baseline HUT, beta- 
blocking drugs were prescribed to all patients ss follows: 1 patient 
was given propranolol (160 mg daily), and 29 patients were glven 
metoprolol (246 * 49 mg daily), with a dose titration period of 14 
days. HUT was repeated after 3 weeks, and 24 patients (80%) had 
negative results (no syncope or anomalous responses). After fur- 
ther dosage adjustment of beta-blockers in nonresponders, a nega- 
tive HUT was obtained in 28 patients (93%). Overall mean metopro- 
101 daily dose was 262 * 60 mg (29 patients), and propranolol was 
administered at 160 mg dally in 1 patient. Thirteen patients (43%) 
reported side effects, none of which required drug withdrawal. At an 
average follow-up of 16 * 4 months, none of the patients experi- 
enced syncope, a statistically significant reduction. Moreover, a sta- 
tistically significant reduction in the number of near-syncopal epi- 
sodes was observed ln comparison to the previous year. None of the 
patients discontinued treatment because of long-term side effects. 
Beta-blockers were well tolerated and achieved a high rate of effi- 
cacy, even in cardioinhlbitory syncopes. In conclusion, in selected 
patients with malignant vasovagal syncope, treatment with meto- 
pro101 or propranolol at relatively high doses is feasible and, if 
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guided by HUT results, is associated with a favorable outcome in 
terms of freedom from syncopa.l recurrences. Appropriate titration 
to achieve the full beta-blocking effect appears to be advisable. Key 
words: beta-blockers, head-up tilt test, neurally mediated syncope. 
INTRODUCTION 
The head-up tilt test (HUT) is widely used to diagnose neurally mediated 
syncope and has been proposed as a means for evaluating drug therapy for 
such syncopal episodes,’ although a low recurrence rate after placebo 
treatment has been reported by some authors.2-7 
Among patients with neurally mediated syncope, some experience 
syncope without warning or prodromes. In these patients syncope may be 
associated with injury or trauma and is called malignant vasovagal syn- 
cope. ‘9’ We believe that p r op y h lactic treatment is strongly indicated in this 
subgroup of patients. Various pharmacologic treatments and even dual- 
chamber pacing have been used for this purpose, and HUT has been pro- 
posed as a guide to long-term prophylaxis.7 
The aim of this study was to assess the efficacy and tolerability of 
treatment with beta-blockers, guided by HUT, in patients with syncope 
associated with trauma or injuries or without prodromes. Specifically, our 
aim was to titrate the dosage of beta-blockers to levels higher than those 
used by previous researchers.7 
PATIENTS AND METHODS 
Patient Selection 
Patients referred to our laboratory for HUT as part of the evaluation 
for unexplained syncope were eligible for this study. Baseline cardiac 
evaluation included a chest roentgenogram, cross-sectional echocardio- 
gram, and, if clinically requested, Holter monitoring and an exercise test. 
A clinical history was obtained from each patient, and the circumstances 
surrounding previous syncopal episodes were reviewed. Presyncope, or 
near-syncope, was defined as an episode of near-loss of consciousness. Pa- 
tients with a positive HUT were included in this study only if clinical 
syncopal episodes were associated with injuries or trauma or occurred 
without prodromes. Verbal informed consent was obtained from all adult 
patients and from parents of patients under 18 years of age. 
Methods 
Patients were studied between 9 AM and noon after an overnight fast 
and during a washout from any cardioactive drug for at least five half- 
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lives. Patients were placed supine on the tilt table, and an intravenous 
catheter was inserted in a peripheral vein. Blood pressure was measured 
by means of an arterial cuff at baseline and then continuously monitored 
noninvasively (Finapress Ohmeda, Englewood, Colorado). After a resting 
period of 10 minutes, patients were tilted upright to 70” during continuous 
electrocardiographic monitoring and maintained in that position for 25 
minutes unless syncope occurred. If patients completed this stage without 
a positive response, they were returned to the supine position and under- 
went HUT while receiving isoproterenol. Isoproterenol testing included 
five steps, each preceded by 10 minutes of recumbency, during which iso- 
proterenol was infused at increasing rates (from 1 to 5 &min), and pa- 
tients were tilted to 80” for 10 minutes. A positive response to HUT was 
defined as sudden loss of consciousness or the development of presyncope 
in association with an abrupt decrease in systolic blood pressure to ~60 
mm Hg, whereas completion of the baseline protocol and isoproterenol 
testing without these responses constituted a negative response to HUT. 
The hemodynamic pattern of the response (cardioinhibitory, vasodepres- 
sive, or mixed) was defined according to VASIS classification.’ 
Treatment with Beta-Blockers 
Patients with a positive HUT who fulfilled the previously mentioned 
requirements (clinical syncope without prodromes or associated with 
trauma), consistent with the definition of malignant vasovagal syncope, 
began treatment with a beta-blocker (metoprolol or propranolol). Prophy- 
lactic treatment was strongly indicated in these highly selected patients, 
and we considered it unethical to either give a placebo or avoid active 
treatment. Initial daily dosages were 50 mg for metoprolol and 80 mg for 
propranolol. The dosages were titrated during a 1Cday period to reach at 
least 100 mg twice a day (BID) for metoprolol and 160 mg for propranolol, 
or to the maximum tolerated dosage. After 3 weeks, patients underwent 
another HUT, including isoproterenol. If this HUT result was positive or 
patients experienced recurrence of syncope or presyncope, a further in- 
crease in the dose of beta-blockers was considered. 
Data concerning the occurrence of adverse events were collected by 
assessing patients’ complaints, and the possible necessity of drug with- 
drawal was evaluated at every visit. 
Long-Term Follow-up 
According to the results of HUT performed under oral treatment with 
beta-blockers, all patients were eligible for long-term prophylaxis. They 
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were followed up in an outpatient clinic every 3 months and were re- 
quested to report the occurrence of any episode of syncope or near-syncope. 
Patients’ reports of adverse events were recorded during the follow-up 
period. 
Statistical Analysis 
Data are expressed as mean f SD. Student’s paired t test was used to 
compare variables before and after treatment. A P value < 0.05 was con- 
sidered statistically significant. 
RESULTS 
Thirty patients 12 to 82 years of age (mean age, 37 * 21 years) with 
syncope without prodromes or associated with trauma or injuries were 
enrolled for the baseline HUT. Twenty-eight (93%) of the 30 patients had 
no evidence of structural heart disease, and 2 patients (7%) had mitral 
valve prolapse with trivial mitral regurgitation. The number of syncopal 
and presyncopal episodes experienced in the previous year is shown in 
Table I. 
Baseline Head-up Tilt Test Response 
At baseline, all 30 patients experienced syncope (during HUT in 
15 [50%1 of the patients and during isoproterenol testing [mean isoproter- 
enol infusion rate 1.6 pg/min; range, 1 to 3 &minl in 15 [50%1 of the 
patients). The pattern of response during HUT was vasodepressor type in 
16 patients (530/o), mixed type in 10 patients (33%), and cardioinhibitory 
type in 4 patients (13%) (mean asystole, 13 f 5 seconds; range, 7 to 19 
seconds). 
Table I. Data on long-term follow-up (16 f 4 months) during treatment with beta-blockers 
(N = 28). 
Clinical Event Previous Year Follow-up 
Syncopal episodes/patient (mean * SD 
2:” ;: 
‘$7” 
0.3 f 0.05* 
11* 
* P < 0.001 versus previous year. 
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Treatment with Beta-Blockers and Control Head-up Tilt 
Test Response 
All patients were treated with beta-blockers; 29 (97%) of the 30 pa- 
tients received metoprolol and 1 patient (3%) received propranolol. Pa- 
tients in the metoprolol group began the treatment with 25 mg BID, with 
progressive titration based on clinical evidence of full-degree beta- 
blockade. At the end of the titration period, the daily dosage for metoprolol 
ranged from 75 to 200 mg BID (mean daily dosage, 246 f 69 mg). Specifi- 
cally, 1 patient received 100 mg; 3 patients, 150 mg; 10 patients, 200 mg; 
14 patients, 300 mg; and 1 patient, 400 mg. One patient received propran- 
0101 160 mg daily. 
At a control HUT performed after 3 weeks, 24 patients (80%) had 
negative results without syncope or anomalous responses. In 4 patients 
(13%) with a persistently positive HUT during beta-blockade coupled with 
spontaneous recurrences of syncope, a further increase in beta-blocking 
dosage was attempted (Table II), and HUT was repeated with the new 
dosage, with satisfactory results (negative HUT). Overall, a negative HUT 
was obtained in 28 patients (93%). Nonresponders to beta-blocker therapy 
included 1 patient with a persistent mixed response (after metoprolol, 
HUT was positive only during isoproterenol testing) and 1 patient with a 
persistent vasodepressive response during isoproterenol testing, similar to 
the baseline HUT. After dosage adjustment, mean daily dosage for meto- 
pro101 was 262 f 60 mg (29 patients). 
Long-Term Follow-up 
The 28 patients who responded to HUT-guided therapy with beta- 
blockers (after titration in 4 patients) were followed up for 16 * 4 months. 
Table II. Effects of further increase in beta-blocker dosage on head-up tilt test (HUT) re- 
sponse in four patients with persistently positive HUT results. 
Patient Sex, 
Aoe (~1 Clinical Picture Drilg 
Dosage at HUT Dosage at HUT 
Positive 
(mu/d) 
Negative 
(w/d) 
F, 27 
M,55 
F, 22 
M, 16 
VD syncope with 
mandibular fracture 
VD syncope with 
facial trauma 
Mixed syncope 
(1 syncope/month) 
Mixed syncope 
with trauma 
Propranolol 160 320 
Metoprolol 200 300 
Metoprolol 150 300 
Metoprolol 100 250 
VD = vasodepressor 
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As shown in Table I, a significant reduction in the number of syncopal or 
near-syncopal episodes was observed in comparison to the previous year 
(P c 0.001). At follow-up (3 months after HUT), heart rate was reduced 
from 74 * 9 beats/min (baseline) to 50 * 6 beats/min (P c 0.005), whereas 
mean cuff blood pressure was statistically unchanged (from 96 * 8 mm Hg 
to 94 * 7 mm Hg). 
Adverse Events 
Treatment-related side effects occurring early (within 3 weeks) or late 
(during long-term follow-up) were evaluated. Among the former, 13 pa- 
tients (43%) experienced side effects: 7 patients experienced fatigue on 
exertion, which improved with physical training; 3 patients had palpita- 
tions, which disappeared by increasing the beta-blocker dosage; 2 patients 
experienced an increase in dreams, which was judged as tolerable; and 1 
patient had cold extremities. During follow-up, 1 patient had persistent 
mild fatigue and 1 patient continued to experience dreams. No drug with- 
drawal was required because of early or late side effects. 
DISCUSSION 
Vasovagal syncope may occur with different characteristics ranging from 
common faints preceded by prodromes to syncope with minimal or no 
warning, often associated with trauma or injuries. The term malignant 
uasouagal syncope has been used for the latter form of syncope,g and, 
because of the potential risks,” prophylactic treatment is required in these 
patients. HUT is the gold standard for establishing the diagnosis of neu- 
rally mediated syncope; however, issues remain about methodology, repro- 
ducibility, and the role of serial HUT in the selection of patients for pro- 
phylactic treatment.2 According to previous studies,11-14 our protocol 
(baseline HUT followed by short increases in the rate of isoproterenol 
infusion) produced results that were reproducible and reliable, and this is 
the basis for assessing the efficacy of a prophylactic treatment. 
A low syncopal recurrence rate has been reported in the follow-up of 
patients with vasovagal syncope not treated with active drugs.2-6 In this 
study, however, we assessed a selected subgroup of patients in whom syn- 
cope was associated with trauma and injuries or occurred without warning 
or prodromes. Prophylactic treatment was strongly indicated in this sub- 
group, and we adopted beta-blocker therapy guided by HUT results. Pre- 
vious studies have proposed various options, including dual-chamber pac- 
ing,15,16 for preventing neurally mediated syncope. 
The present study showed how, in selected patients, suppression of 
HUT-induced syncope is related to a favorable outcome during follow-up. 
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Moreover, HUT-guided treatment may be helpful because careful titration 
of beta-blockers is advisable and because increasing the dosages of beta- 
blockers after a positive HUT may lead to a better drug response and a 
more favorable outcome. In our experience, relatively high doses of beta- 
blocking drugs are required to achieve negative responses with HUT, and 
this finding is consistent with the proposed pathophysiologic hypothesis 
for vasovagal syncope,17’1s because inhibition of increased myocardial ino- 
tropy is required in these patients. 
The mean dosage of beta-blockers (primarily metoprolol) used in this 
study is higher than the dosage of metoprolol or atenolol used in other 
studies, where atenolol was prescribed at 50 mg once daily5p6p1’ or meto- 
pro101 at 25 to 50 mg BID.20 In a study by Mahanonda et a1,21 atenolol 
showed a substantial decrease in the recurrence of symptoms in a random- 
ized, controlled trial of 42 patients who received 50 to 100 mg of the drug 
daily. In that study, 21 62% of patients receiving atenolol had a negative 
HUT compared with 5% receiving placebo, and atenolol efficacy results 
were even higher (38% of patients), as reported by Fitzpatrick et a1.5 The 
likelihood of dose-related differences in HUT response in patients receiv- 
ing atenolol was not investigated by Mahanonda et a121; nevertheless, it 
may be a reasonable explanation for these discrepancies. 
Concern regarding the risk of worsening asystolic response by admin- 
istering beta-blockers in patients with cardioinhibitory syncope22 was not 
supported, because the four patients with asystolic responses were well 
controlled by beta-blockers, without paradoxic responses. 
In this study, a significant and impressive reduction in either syncopal 
or near-syncopal episodes was observed during long-term follow-up. It 
could be argued that the reduction in syncopal episodes was related to 
the patients’ ability to abort the episode once diagnosis was confirmed 
instead of being a true pharmacologic effect. However, we believe that 
the concomitant reduction in near-syncopal episodes strongly suggests a 
true pharmacologic effect. Although placebo-controlled trials are required 
in patients with vasovagal syncope, the use of a placebo in patients 
with traumatic syncope is questionable. Treatment-related adverse events 
in our study were tolerable, and none of the patients required drug 
withdrawal. 
CONCLUSION 
In selected patients with malignant vasovagal syncope, treatment with 
metoprolol or propranolol at relatively high doses is feasible and, if guided 
by HUT results, is associated with a favorable outcome in terms of freedom 
from syncopal recurrences. 
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